2022 · Expert opinion on biological therapy · paywalled
IBD goes home: from telemedicine to self-administered advanced therapies
Solitano et al.
The finding, in our words
The paper reviews the use of home-based fecal calprotectin and dried blood spot testing as effective methods for remote monitoring of inflammatory bowel disease when in-person visits are not possible. This supports decentralised diagnostics by enabling patient-centric sampling and remote patient monitoring in chronic disease management.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
In a 20-person proof-of-concept pilot among veterans with HIV, remote self-collection of dried blood spots for phosphatidylethanol monitoring was feasible and acceptable, with high return and analysis rates and positive feedback; a small first step toward decentralised alcohol biomarker monitoring rather than proof of it.
Sheinfil et al., Journal of substance use and addiction treatment (paywalled) · source ↗
This study validated a method combining quantitative dried blood spots with DNA methylation analysis to monitor B-cell counts remotely, achieving 100% sensitivity and specificity for a specific clinical threshold. This decentralised approach facilitates patient-centric therapeutic drug monitoring for anti-CD20 therapies by overcoming the logistical barriers of regular venous sampling.
Tallantyre et al., Multiple sclerosis (paywalled) · source ↗
In an adolescent with cerebral palsy undergoing a home-based, remotely supervised sprint-intensity interval training intervention, dried blood spot testing demonstrated a 37.8% reduction in triglycerides and a 15.4% improvement in total cholesterol to HDL ratio. This illustrates how remote microsampling can support decentralized metabolic monitoring in pediatric disability rehabilitation.
The Drawbridge OneDraw device enabled home blood collection with high acceptability, as 76 per cent of participants preferred it to finger-prick or venous methods and reported significantly lower pain scores. In a remote study of 4023 participants, sample return rates stayed above 89 per cent across three timepoints over six months, and antibody results agreed well with venous blood in a validation subset of 120 participants.
Koulman et al., Journal of telemedicine and telecare · source ↗
The COVID-OUT trial showed a fully decentralised, multicentre randomised trial could be completed with only 1.4% loss to follow-up using electronic consent, prepackaged investigational product, and remote outcome confirmation. This demonstrates decentralised trials can achieve high retention without in-person contact, directly informing decentralised diagnostic study design.
Avula et al., Journal of clinical and translational science · source ↗